{"id":"W2126275851","doi":"10.1056/nejmoa072113","title":"Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer","year":2007,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3053,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Sanofi; Genentech; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Medicine; Paclitaxel; Bevacizumab; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}